智通财经APP讯，东阳光药(06887)公布，2025年12月31日耗资约2106.32万港元回购47.6万股股份。 ...

呈交日期： 2025年12月31日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 廣東東陽光藥業股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06887 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...

Core Viewpoint - Dongyangguang's actual controller Guo Meilan has transferred her stakes in Luyuan Yunen Electronics (71.75%) and Luyuan Xinjing Technology (74.63%) to Zhang Yushua, enabling him to indirectly hold 100% of Dongyangguang Group and 38.70% of the listed company Dongyangguang [1][4] Group 1: Share Transfer and Ownership Structure - Guo Meilan, aged 62, has transferred her entire stakes in two companies to her son Zhang Yushua, who was born in 1987 [1] - After the transfer, Guo Meilan no longer holds any shares in the two companies and thus does not indirectly hold shares in Dongyangguang [1] - Zhang Yushua now indirectly holds 11.65 billion shares of Dongyangguang, representing 38.70% of the total share capital [1] Group 2: Company Performance and Business Expansion - Dongyangguang Group achieved a record total output of over 51 billion yuan in 2023, with total assets exceeding 80 billion yuan and cumulative taxes paid over 20 billion yuan [4] - The group has expanded its business from electronic materials to biomedicine and health, and is actively acquiring in the computing power sector [4][11] - Dongyangguang's stock market value is approximately 26 billion yuan, with the group directly holding 6.2 billion shares and indirectly holding 5.45 billion shares of the listed company [4] Group 3: Financial Performance - In the first half of the year, Dongyangguang reported a revenue of 1.938 billion yuan, a year-on-year decline of 23.95%, and a net profit of 46.37 million yuan, turning from profit to loss [8] - For the first three quarters, Dongyangguang achieved a revenue of 10.97 billion yuan, with a year-on-year increase of 109.7%, and a net profit of 906 million yuan, up 189.8% [8][10] - The company plans to acquire Qinhuai Data for 28 billion yuan to create a closed-loop business model in the computing power sector [11]

【财华社讯】东阳光药(06887.HK)公布，董事会接获公司控股股东集团成员张寓帅及郭梅兰告知，鉴于 郭梅兰决定退休并减少参与集团业务，于2025年12月29日，张寓帅与郭梅兰订立股权转让协议，据此郭 梅兰将其分别于乳源寓能电子及乳源新京科技持有的71.75%股权及74.63%股权转让张寓帅，转让之名 义代价各分别为人民币1.00元。郭梅兰为张寓帅的母亲。 完成相关监管备案及股权转让交割后，张寓帅将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭梅兰将不再为控股股东集团成员。 董事认为，股权转让对公司整体财务及营运不会产生任何不利影响。 本文源自：财华网 ...

董事认为，股权转让对本公司整体财务及营运不会产生任何不利影响。 智通财经APP讯，东阳光药(06887)发布公告，本公司董事会接获张寓帅先生(张先生)及郭梅兰女士(郭女 士)(各自作为本公司的控股股东集团成员)(控股股东)告知，鉴于郭女士决定退休并减少参与本集团业 务，于2025年12月29日，张先生与郭女士订立股权转让协议，郭女士将其分别于乳源瑶族自治县寓能电 子实业有限公司(乳源寓能电子)及乳源瑶族自治县新京科技发展有限公司(乳源新京科技)持有的71.75% 股权及74.63%股权转让张先生，转让的名义代价各分别为人民币1.00元(股权转让)。郭女士为张先生的 母亲。 完成相关监管备案及股权转让交割后，张先生将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭女士将不再为控股股东集团成员。 ...

董事认为，股权转让对本公司整体财务及营运不会产生任何不利影响。 完成相关监管备案及股权转让交割后，张先生将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭女士将不再为控股股东集团成员。 东阳光（600673）药(06887)发布公告，本公司董事会接获张寓帅先生(张先生)及郭梅兰女士(郭女士)(各 自作为本公司的控股股东集团成员)(控股股东)告知，鉴于郭女士决定退休并减少参与本集团业务，于 2025年12月29日，张先生与郭女士订立股权转让协议，郭女士将其分别于乳源瑶族自治县寓能电子实业 有限公司(乳源寓能电子)及乳源瑶族自治县新京科技发展有限公司(乳源新京科技)持有的71.75%股权及 74.63%股权转让张先生，转让的名义代价各分别为人民币1.00元(股权转让)。郭女士为张先生的母亲。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 內幕消息 控股股東集團成員間的股權轉讓 本 公 告 乃 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱 「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例第XIVA部下的內幕消息條文（ 定義見上市規則 ） 而作出。 股權轉讓 本公司董事（「董事」）會（「董事會」）接獲張寓帥先生（「張先生」）及郭梅蘭女士（「郭 女士」）（ 各自作為本公司之控股股東集團成員（ 定義見上市規則 ））（「控股股東」）告 知 ， 鑒 於 郭 女 士 決 定 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) is a leading company in the influenza sector with a solid foundation and a rich pipeline of innovative products, focusing on three main areas: anti-infection, chronic diseases, and oncology. The company maintains a leading position in the anti-infection field, particularly in influenza, hepatitis C, and hepatitis B, and has been given a "Buy" rating by Huafu Securities [1]. Group 1: Anti-Infection - The company holds a leading position in the influenza market, with Oseltamivir ranking first in domestic market share and possessing the largest production base globally, ensuring sufficient supply capacity [2]. - The hepatitis C pipeline includes the approval of pan-genotypic therapies, with NMPA approvals for Phosphoribosyl-1-pyrophosphate and Acalabrutinib expected in February and March 2025, respectively [2]. - For hepatitis B, the fastest progress is seen with Mofetil, which is the only product in China entering Phase III clinical trials, while the siRNA therapy (HECN30227) is set to enter clinical stages in October 2025 [2]. Group 2: Chronic Diseases - Ifenprodil is identified as a potential blockbuster drug (BIC) targeting the $4 billion global market for idiopathic pulmonary fibrosis, with Phase I trials completed in China and the US, and promising Phase II data showing a 96% delay in decline compared to placebo [3]. - Insulin products are nearing FDA approval, with Glargine expected to receive BLA approval in the first half of 2026, while Aspart has a Pre-IND application submitted, with plans to file for BLA by the end of 2025 and anticipate approval by the end of 2026 [3]. Group 3: Oncology - The company expects the approval of Clifosfamide for acute myeloid leukemia (AML) by 2027, having formed a partnership with 3SBio for this product [4]. - The oncology pipeline is rich, including Lenvatinib (Phase III) for esophageal cancer, HEC53856 (Phase II) for chemotherapy-induced anemia, and HEC201625 (upcoming IND) as an oral PD-L1 small molecule, with ongoing efforts in new technology areas such as ADC and TCE [4]. Group 4: Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 250 million, 540 million, and 930 million yuan for the years 2025, 2026, and 2027, respectively, with price-to-sales ratios of 4.5, 3.7, and 3.2 times, indicating a strong value proposition compared to peers [5].

Core Viewpoint - Dongyang Sunshine Pharmaceutical has been awarded the "Annual Outstanding Biopharmaceutical Enterprise" at the "Technology Empowerment · Capital Breakthrough" sharing session, highlighting its achievements in innovation and research in the biopharmaceutical sector [1][3]. Company Overview - Dongyang Sunshine Pharmaceutical (06887.HK) is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generics, and biosimilars. The company emphasizes innovation, internationalization, and sustainability, driven by independent research and development [3]. - The company has established a comprehensive R&D system over 20 years, employing over 1,100 R&D personnel, including more than 20 foreign and returned experts. It has received the Guangdong Province Innovation Team title six times and holds over 2,500 patents [3][4]. Strategic Focus - The company adheres to "independent innovation" as its core strategy, deepening its "internationalization" efforts while focusing on three key therapeutic areas: infections, chronic diseases, and tumors. It employs diverse technologies, including small molecules, antibodies, small nucleic acids, ADC, and cell therapies [4]. - Dongyang Sunshine has launched three original innovative drugs and has 49 first-class innovative drugs in development, with one nearing market launch and ten in clinical phases II and III. Several pipeline products have "First in class" or "Best in class" potential [4]. Recent Achievements - In 2024, two candidate drugs are expected to achieve external cooperation and licensing agreements, with a total transaction value exceeding $1 billion [4]. - The company is addressing the global challenge of functional cure for hepatitis B with its small nucleic acid drugs and has the only complete independent intellectual property treatment plan for pan-genotype hepatitis C in China [4]. - Dongyang Sunshine's insulin product, Glargine, is set to be approved for sale in the U.S., making it the first Chinese company to market insulin in the U.S. Additionally, its new diabetes drug, Ologliptin, is also nearing approval [4].

12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选 中，百利天恒(688506.SH)、东阳光药(06887.HK)、东曜药业-B(01875.HK)、和铂医药-B(02142.HK)、华领医药-B(02552.HK)、先声药业(02096.HK)、亚盛 医药(06855.HK/AAPG.US)、真实生物8家企业荣获"年度卓越生物医药企业"奖项。（排名不分先后，按公司首部字母顺序排列） "年度卓越生物医药企业"是从技术创新、研发实力、成果转化等多方面综合评估，旨在表彰在生物医药领域具有自主核心技术、持续创新并能高效将科研成 果转化为临床或商业应用的领军企业。本次评选通过定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角兽公司排行榜。此次"金格奖"上市公司评选覆盖港交 所、上交所、深交所、纽交所、美国证券交易所、纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 ...